Erlotinib and Everolimus in Treating Patients With Metastatic Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

January 31, 2009

Study Completion Date

February 28, 2009

Conditions
Breast Cancer
Interventions
DRUG

erlotinib

"Levels:~* 1 Erlotinib 50 mg/d~* 2 Erlotinib 50 mg/d~ * 1 Erlotinib 100 mg/d~ * 2 Erlotinib 100 mg/d~ * 3 Erlotinib 150 mg/d~ * 4 Erlotinib 150 mg/d"

DRUG

RAD001

"Levels~minus 1: RAD001 2.5 mg/d~minus 2: RAD001 2.5 every other day~1. RAD001 2.5 mg per day~2. RAD001 5 mg per day~3. RAD001 10 mg per day~4. RAD001 10 mg per day"

Trial Locations (3)

37064

Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville

Vanderbilt-Ingram Cancer Center at Franklin, Nashville

37232-6838

Vanderbilt-Ingram Cancer Center, Nashville

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Vanderbilt-Ingram Cancer Center

OTHER

NCT00574366 - Erlotinib and Everolimus in Treating Patients With Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter